Treatment of pediatric acute lymphoblastic leukemia

Pediatric Clinics of North America

Volumn 62, Issue 1, 2015, Pages 61-73

  Cooper, Stacy L ^a   Brown, Patrick A ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute lymphoblastic leukemia; Leukemia treatment; Risk based stratification

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLINATUMOMAB; BORTEZOMIB; CLOFARABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MOXETUMOMAB PASUDOTOX; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ALLERGIC REACTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE NECROSIS; BRAIN DISEASE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARDIOTOXICITY; CHILDHOOD CANCER; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CONJUNCTIVITIS; CONSOLIDATION CHEMOTHERAPY; CYTOKINE RELEASE SYNDROME; DRUG RECHALLENGE; DRUG SAFETY; FLU LIKE SYNDROME; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; IMMUNOPHENOTYPING; INAPPROPRIATE VASOPRESSIN SECRETION; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; MAINTENANCE CHEMOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OVERALL SURVIVAL; PANCREATITIS; PATIENT SELECTION; PSYCHOSIS; REVIEW; RISK ASSESSMENT; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VOMITING; CHILD; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHILD; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84915747488     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2014.09.006     Document Type: Review

References (52)

1. Gaynon P.S., Angiolillo A.L., Carroll W.L., et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia 2010, 24(2):285-297.
2. Möricke A., Zimmermann M., Reiter A., et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 2005, 217(6):310-320.
3. Reiter A., Schrappe M., Ludwig W.D., et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994, 84:3122-3133.
4. Haydu J.E., Ferrando A.A. Early T-cell precursor acute lymphoblastic leukaemia. Curr Opin Hematol 2013, 20(4):369-373.
5. Gerr H., Zimmermann M., Schrappe M., et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol 2010, 149(1):84-92.
6. Harris M.B., Shuster J.J., Carroll A., et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992, 79(12):3316-3324.
7. Seeger K., Stackelberg A.V., Taube T., et al. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. JClin Oncol 2001, 19(13):3188-3193.
8. Pollock B.H., DeBaun M.R., Camitta B.M., et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. JClin Oncol 2000, 18(4):813-823.
9. Rubnitz J.E., Wichlan D., Devidas M., Children's Oncology Group, et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. JClin Oncol 2008, 26(13):2186-2191.
10. Heerema N.A., Carroll A.J., Devidas M., et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. JClin Oncol 2013, 31(27):3397-3402.
11. Schrappe M., Hunger S.P., Pui C.H., et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. NEngl J Med 2012, 366(15):1371-1381.
12. Borowitz M.J., Devidas M., Hunger S.P., Children's Oncology Group, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008, 111(12):5477-5485.
13. Conter V., Bartram C.R., Valsecchi M.G., et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115(16):3206-3214.
14. Escherich G., Zimmermann M., Janka-Schaub G., et al. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. Pediatr Blood Cancer 2013, 60(2):254-257.
15. Mitchell C.D., Richards S.M., Kinsey S.E., et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005, 129(6):734-745.
16. Avramis V.I., Sencer S., Periclou A.P., et al. Arandomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002, 99(6):1986-1994.
17. Seibel N.L., Steinherz P.G., Sather H.N., et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008, 111(5):2548.
18. Bhatia S., Landier W., Shangguan M., et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. JClin Oncol 2012, 30(17):2094-2101.
19. Brackett J., Schafer E.S., Leung D.H., et al. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Pediatr Blood Cancer 2014, 61(6):1114-1117.
20. Schmiegelow K., Schrøder H., Gustafsson G., et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. JClin Oncol 1995, 13(2):345-351.
21. Schmiegelow K., Heyman M., Gustafsson G., et al. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia 2010, 24(4):715-720.
22. Eden T.O., Pieters R., Richards S., et al. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia-an individual patient data meta-analysis involving 5,659 children. Br J Haematol 2010, 149(5):722-733.
23. Evans A.E., Gilbert E.S., Zandstra R. The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). Cancer 1970, 26:404.
24. Matloub Y., Lindemulder S., Gaynon P.S., et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 2006, 108(4):1165-1173.
25. Pui C.H., Campana D., Pei D., et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. NEngl J Med 2009, 360(26):2730-2741.
26. Sirvent N., Suciu S., Rialland X., et al. Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. Eur J Cancer 2011, 47(2):239-247.
27. Hochberg J., Khaled S., Forman S.J., et al. Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission. Br J Haematol 2013, 161(1):27-42.
28. Hilden J.M., Dinndorf P.A., Meerbaum S.O., et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006, 108(2):441-451.
29. Pieters R., Schrappe M., De Lorenzo P., et al. Atreatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370(9583):240-250.
30. Pichler H., Reismüller B., Steiner M., et al. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate-a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group. Br J Haematol 2013, 161(4):556-565.
31. O'Brien S.H., Klima J., Termuhlen A.M., et al. Venous thromboembolism and adolescent and young adult oncology inpatients in US children's hospitals, 2001 to 2008. JPediatr 2011, 159(1):133-137.
32. Ram R., Wolach O., Vidal L., et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol 2012, 87(5):472-478.
33. Berg S.L., Blaney S.M., Devidas M., et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. JClin Oncol 2005, 15:3376-3382.
34. Rubnitz J.E., Onciu M., Pounds S., et al. Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood 2009, 113(21):5083-5089.
35. Whitlock J.A. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006, 135(5):595-602.
36. Schultz K.R., Bowman W.P., Aledo A., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. JClin Oncol 2009, 27(31):5175-5181.
37. Locatelli F., Schrappe M., Bernardo M.E., et al. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012, 120(14):2807-2816.
38. Chessells J.M. Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol 1998, 102(2):423-438.
39. Nguyen K., Devidas M., Cheng S.C., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008, 22(12):2142-2150.
40. Coustan-Smith E., Gajjar A., Hijiya N., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004, 18(3):499-504.
41. Eckert C., von Stackelberg A., Seeger K., et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. Eur J Cancer 2013, 49(6):1346-1355.
42. Gandemer V., Chevret S., Petit A., et al. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol. Haematologica 2012, 97(11):1743-1750.
43. Hof J., Krentz S., van Schewick C., et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. JClin Oncol 2011, 29(23):3185-3193.
44. Parker C., Waters R., Leighton C., et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010, 376(9757):2009-2017.
45. Rivera G.K., Hudson M.M., Liu Q., et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood 1996, 88(3):831-837.
46. Wofford M.M., Smith S.D., Shuster J.J., et al. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. JClin Oncol 1992, 10(4):624-630.
47. Levine J.E., Barrett A.J., Zhang M.J., et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008, 42(3):201-205.
48. Brentjens R.J., Curran K.J. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19antigen. Hematology Am Soc Hematol Educ Program 2012, 2012:143-151.
49. Hoffman L.M., Gore L. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol 2014, 4:63.
50. Kreitman R.J., Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011, 17(20):6398-6405.
51. Burke M.J., Bhatla T. Epigenetic modifications in pediatric acute lymphoblastic leukemia. Front Pediatr 2014, 2:42.
52. Pui C.H., Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007, 6:149-165.